Vector Development
Lentiviral vector may be used to study and treat proliferative diseases
Published in Gene Therapy Weekly, November 9th, 2006
"We have constructed a lentiviral vector with expression limited to cells presenting active E2F-1 protein, a potential advantage for gene therapy of proliferative diseases. For the FE2FLW vector, the promoter region of the human E2F-1 gene was utilized to drive expression of luciferase cDNA, included as a reporter of viral expression.
"Primary, immortalized, and transformed cells were transduced with the FE2FLW vector and cell cycle alterations were induced with serum...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-11-09)
More Articles from Gene Therapy Weekly
- Cholangiocarcinoma
Cholangiocarcinoma cell growth inhibited by receptor ligand - Genetics & Genomics
MicroRNA expression detected by RNA oligonucleotide hybridization - Genetics & Genomics
Therapeutic exon skipping achieved in Duchenne muscular dystrophy - RNA Interference
RNA interference-mediated enzyme silencing achieves therapeutic benefit - Cancer Gene Therapy
Reports outline cancer gene therapy research from West Virginia University, Mary Babb Randolph Cancer Center - Cancer Gene Therapy
Research on cancer gene therapy detailed by scientists at Massachusetts Institute of Technology - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
